Efficacy Testing of Chenopodium Formosanum Extracts on Skin Beauty

Not Applicable

Completed

• Conditions: Skin Condition

• Registration Number: NCT05591352
• Lead Sponsor: TCI Co., Ltd.

Brief Summary

To assess Chenopodium formosanum extracts on skin condition improvement

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-10-19
• Study First Submitted QC: 2022-10-19
• Study First Posted: 2022-10-24
• Study Start: 2022-11-01
• Primary Completion: 2023-01-13
• Study Completion: 2023-09-30
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-07
• Last Update Posted: 2023-11-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Healthy adults aged above 20 years old

Exclusion Criteria

• Subject who is not willing to participate in this study.
• Patients with diseases of the skin, liver, kidney.
• Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder.
• Female who is pregnant or nursing or planning to become pregnant during the course of the study.
• Received facial laser therapy, chemical peeling or UV overexposure (> 3 hr/week) in the past 4 weeks.
• Constant drug use
• Students who are currently taking courses taught by the principal investigator of this trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The change of skin wrinkles	Change from Baseline skin wrinkles at 8 weeks	VISIA Complexion Analysis System was utilized to measure skin wrinkles. Units: arbitrary units
The change of skin elasticity	Change from Baseline skin elasticity at 8 weeks	Cutometer® MPA580 was utilized to measure skin elasticity. Units: arbitrary units
The change of skin texture	Change from Baseline skin texture at 8 weeks	VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units
The change of skin collagen density	Change from Baseline skin collagen density at 8 weeks	DermaLab® Series SkinLab Combo was utilized to measure skin pores. Units: arbitrary units

Secondary Outcome Measures

Name	Time	Method
The change of transepidermal water loss (TEWL)	Change from Baseline TEWL at 8 weeks	Tewameter® TM 300 was utilized to measure TEWL. Units: g/hm²
The change of skin pores	Change from Baseline skin pores at 8 weeks	VISIA Complexion Analysis System was utilized to measure skin pores. Units: arbitrary units
The change of skin melanin index	Change from Baseline skin melanin index at 8 weeks	Mexameter® MX18 was utilized to measure skin melanin index. Units: arbitrary units
The change of skin L* value	Change from Baseline L* value at 8 weeks	Chroma Meter MM500 was utilized to measure skin L\* value. Units: arbitrary units, 0-100
The change of skin erythema index	Change from Baseline skin erythema index at 8 weeks	Mexameter® MX18 was utilized to measure skin erythema index. Units: arbitrary units
The change of skin moisture	Change from Baseline skin moisture at 8 weeks	Corneometer® CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120
The change of AGEs of blood	Change from Baseline AGEs at 8 weeks	Fasting venous blood was sampled to measure concentrations of AGEs

Trial Locations

Locations (1)

Chia Nan University of Pharmacy & Science; 🇨🇳 Tainan City, Taiwan